Get to the Clinic Faster

At Lonza, we understand the challenges facing biotherapeutic protein and vaccine manufacturers related to the time and costs inherent in the drug discovery and development process. Light Path™ Protein Production Services are efficient, focused technology and production offerings for biotherapeutic proteins and vaccines. Light Path™ services allow you to leverage Lonza's industry-accepted mammalian and microbial expression platforms, that have met with consistent regulatory approval, to help you meet your Preclinical and Phase I manufacturing needs in a lean, cost-effective manner.

Light Path™ Services include:

Gene to non-GMP or cGMP production services

Offerings for both mammalian and microbial expressed proteins and monoclonal antibodies

Technology access at a Lonza facility without research license fees

Protein production for manufacturability, safety and efficacy testing

Services for a wide range of biotherapeutic and vaccine candidates

Our goal is to help you increase your biotherapeutic protein and vaccine candidates' success throughout the discovery and development process. Our team of experienced and dedicated staff will work with you to design the best Light Path™ program to meet your protein production needs. We are committed to being your partner now and for future long-term, commercial agreements. Partnering with Lonza allows you to take advantage of our proven expression technology platforms and extensive protein development experience, over 30 years and hundreds of biotherapeutic molecules.

Lower your risk, remain flexible and stay focused.

The focused offerings of the Light Path™ Protein Production Services can help reduce the time to IND/IMPD filings.

Rapid Host Screening

Light Path™ Host Screening is a customized service to accelerate the selection of the optimal expression host system for your protein of interest. Our Host Screening Service allows you to make an informed decision regarding which expression system is best suited for your protein production, without the added cost of license fees.

As a host screen customer, your molecule will be expressed in both our Mammalian GS Xceed™ and Microbial XS™ Expression Systems at Lonza's Process Development Centers. The use of production-ready cell lines provides future cost and time advantages when you are ready to manufacture batches for immunogenicity, safety, efficacy, and other Preclinical and Phase I needs.

Light Path™ Host Screening provides rapid identification of your best option, in terms of yield, for successful protein expression. Quick expression system identification will allow you to move seamlessly into small-scale manufacturing with our Light Path™ Discovery Protein Production Service.

Discovery Production Services

Light Path™ Discovery Protein Production is Lonza's streamlined service for small-scale, non-GMP production of proteins and monoclonal antibodies. Offerings include both mammalian and microbial expression technologies with research access to our systems with no license fee while work is performed at a Lonza facility. Our Discovery services can provide mg quantities of non-GMP product for your discovery through early development stage needs.

Mammalian Discovery Service Includes

Expression: GS Xceed™ System

Host Cell Line: CHO

Purification: Protein A or G to purify antibodies, affinity or other options available

Product Assessment: SDS-PAGE, HPLC, Western Blot, and Endotoxin, as applicable

Timeline: 4-12 weeks post gene synthesis

Non-GMP product: 10 - 500 mg or clarified supernatant

Microbial Discovery Service Includes:

Expression: XS™ System

Host Strain: Sugar inducible E. coli

Expression of tagged or untagged native proteins

Purification: Affinity chromatography to purify tagged proteins

Product Assessment: SDS-PAGE, SE-HPLC, and Western Blot, as applicable

Timeline: 4-12 weeks post gene synthesis

Non-GMP product: 10 - 250 mg

Light Path™ Mammalian and Microbial Discovery Protein Production Services can provide you with sufficient material to facilitate the selection and ranking of lead candidates from discovery phase manufacturability and safety assessments to preliminary in vivo functional studies.

Development Production Services

Cell Line to cGMP in 9 to 11 Months

As you move out of the discovery phase and into clinical development, you will need an increase in the quantity and quality of your product. Our Light Path™ Mammalian and Microbial Development Protein Production Services enable you to continue with Lonza for scale-up and cGMP manufacture of your protein or antibody for Preclinical through IND/IMPD product needs. Research access to our expression systems is available with no license fee while the work is performed at a Lonza facility.

Mammalian Development Service Includes:

Optional non-GMP pilot run

cGMP scale-up options from 200 L to 1000 L

Microbial Development Service Includes:

Option to use XS™ Technologies or client-provided strain

Optional non-GMP pilot run

cGMP scale-up options from 20 L to 70 L

Multiple site manufacturing options

More information on Light Path™ Protein Production Services can be found in our Mammalian and Microbial Biopharmaceutical sections.